Azam, Camille
Buscail, Louis http://orcid.org/0000-0003-4276-1003
Culetto, Adrian
Lapeyre-Mestre, Maryse http://orcid.org/0000-0002-5494-5873
Article History
Accepted: 16 January 2022
First Online: 18 February 2022
Declarations
:
: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This work has been conducted in the context of a research master training of Camille Azam at the University of Toulouse.
: Camille Azam, Adrian Culetto, and Maryse Lapeyre-Mestre declare that they have no conflict of interest. Louis Buscail has received research grants from CVASTHERA pharmaceutical.
: This study did not required any specific ethics approval, case reports included have been already published in the scientific literature, or are accessible through open or restricted national or international pharmacovigilance databases.
: Not applicable.
: Not applicable.
: As indicated in the article, data extracted from the open pharmacovigilance databases can be extracted by any individual. Information from databases with a restricted access can be obtained on request from the Uppsala Monitoring Center and/or from national pharmacovigilance centers. All data used and generated in the literature review are presented in the main text of the article or in the ESM. All literature cases are available as published on request.
: Not applicable.
: MLM had the idea for the article, CA and MLM performed the literature search, data extraction and data analysis, and the pharmacovigilance database search, LB and EC provided their list of references and published case series, CA drafted the first draft, and all authors revised the work and approved the final manuscript.